Patents Assigned to NEXIMMUNE, INC.
  • Compositions and methods for immunotherapy
    Patent number: 11712477
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: August 1, 2023
    Assignee: NexImmune, Inc.
    Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
  • Nanoparticle compositions and methods for immunotherapy
    Patent number: 11510981
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 29, 2022
    Assignee: NexImmune, Inc.
    Inventor: Bruce McCreedy
  • T cell compositions with improved phenotypic properties
    Patent number: 11007222
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: NEXIMMUNE, INC.
    Inventors: Mathias Oelke, Kristi Jones, Sojung Kim, Lauren Suarez, Ken Carter, Scott Carmer, Dan Bednarik, Vineetha Edavana, Emily Lu
  • Nanoparticle compositions and methods for immunotherapy
    Patent number: 10632193
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: April 28, 2020
    Assignee: NEXIMMUNE, INC.
    Inventor: Bruce McCreedy